✦ LIBER ✦

Hospital environment and invasive aspergillosis in patients with hematologic malignancy

✍ Scribed by Linda D. Lee; Ray Y. Hachem; Matthew Berkheiser; Brenda Hackett; Ying Jiang; Issam I. Raad

Book ID: 116198474
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 118 KB
Volume: 40
Category: Article
ISSN: 1527-3296
DOI: 10.1016/j.ajic.2011.03.031

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Invasive Aspergillosis in Patients with

Invasive Aspergillosis in Patients with Hematologic Malignancies

✍ Dr. Nathan P. Wiederhold; Dr. Russell E. Lewis; Dimitrios P. Kontoyiannis 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB

Invasive oral aspergillosis in immunocom

Invasive oral aspergillosis in immunocompromised patients with hematologic malignancies

✍ T. Sugata; S. Tanaka; Y. Myoken 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 113 KB

Risk factors for invasive aspergillosis

Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies

✍ Mühlemann, K; Wenger, C; Zenhäusern, R; Täuber, M G 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 106 KB

Treatment of invasive aspergillosis in c

Treatment of invasive aspergillosis in children with hematologic malignancies

✍ Walid Abuhammour; Rashed A. Hasan 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 921 KB

Early surgical treatment of invasive ora

Early surgical treatment of invasive oral aspergillosis in neutropenic patients with hematologic malignancies

✍ Y. Myoken; S. Tanaka; T. Sugata 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 100 KB

Amphotericin B lipid complex versus lipo

Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy

✍ Ray Y. Hachem; Maha R. Boktour; Hend A. Hanna; Rola N. Husni; Harrys A. Torres; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract ## BACKGROUND. Invasive aspergillosis (IA) is a major cause of morbidity and mortality in patients with hematologic malignancy (HM). There are 2 lipid formulations of amphotericin B (AMB) currently in widespread use: AMB lipid complex (ABLC) and liposomal AMB (L‐AMB). There are limited